Patient reported outcome measures in rare diseases: a narrative review

Anita Slade, Fatima Isa, Derek Kyte, Tanya Pankhurst, Larissa Kerecuk, James Ferguson, Graham Lipkin, Melanie Calvert, Anita Slade, Fatima Isa, Derek Kyte, Tanya Pankhurst, Larissa Kerecuk, James Ferguson, Graham Lipkin, Melanie Calvert

Abstract

Background: Rare diseases can lead to a significant reduction in quality of life for patients and their families. Ensuring the patients voice is central to clinical decision making is key to delivering, evaluating and understanding the efficacy of therapeutic interventions. Patient reported outcome measures (PROMs) are used to capture the patient's views about their health status and facilitate our understanding of the impact of these diseases and their treatments on patient's quality of life and symptoms.

Main text: This review explores some of the current issues around the utilisation of PROMs in rare diseases, including small patient populations and dearth of valid PROMs. Difficulties in validating new or current PROMs for use in clinical trials and research are discussed. The review highlights potential solutions for some of the issues outlined in the review and the implementation of PROMs in research and clinical practice are discussed.

Conclusion: Patient input throughout the development of PROMs including qualitative research is essential to ensure that outcomes that matter to people living with rare disease are appropriately captured. Given the large number of rare diseases, small numbers of patients living with each condition and the cost of instrument development, creative and pragmatic solutions to PROM development and use may be necessary. Solutions include qualitative interviews, modern psychometrics and resources such as item banking and computer adaptive testing. Use of PROMs in rare disease research and clinical practice offers the potential to improve patient care and clinical outcomes.

Keywords: Outcome assessments; Patient reported outcome measures; Quality of life; Rare diseases; Rare disorders.

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

    1. Global Genes. Rare diseases: facts and statistics. . Accessed 2 Nov 2017.
    1. EURORDIS. The voice of rare disease patients in Europe. . Accessed 15 Sept 2017.
    1. Limb L, Nutt S, Sen A. Experiences of rare diseases: an insight from patients and families: UK RD; 2010. . Accessed 9 Sept 2017.
    1. EMA. Orphan medicines in the EU-leaving no patient behind. 2017. Accessed 8 Jan 2018.
    1. Johansen H, Dammann B, Andresen I-L, Fagerland MW. Health-related quality of life for children with rare diagnoses, their parents’ satisfaction with life and the association between the two. Health Qual Life Outcomes. 2013;11:152. doi: 10.1186/1477-7525-11-152.
    1. Schalet BD, Pilkonis PA, Yu L, Dodds N, Johnston KL, Yount S, Riley W, Cella D. Clinical validity of PROMIS depression, anxiety, and anger across diverse clinical samples. J Clin Epidemiol. 2016;73:119–127. doi: 10.1016/j.jclinepi.2015.08.036.
    1. Spillmann RC, McConkie-Rosell A, Pena L, Jiang Y-H, Schoch K, Walley N, Sanders C, Sullivan J, Hooper SR, Shashi V. A window into living with an undiagnosed disease: illness narratives from the undiagnosed diseases network. Orphanet J Rare Dis. 2017;12:71. doi: 10.1186/s13023-017-0623-3.
    1. EURORDIS. The Voice of 12,000 Patients: Experiences and Expectations of Rare Disease Patients on Diagnosis and Care in Europe: EURORDIS Rare Diseases Europe; 2009. . Accessed 9 Sept 2017
    1. Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy. 2015;119:964–979. doi: 10.1016/j.healthpol.2014.12.016.
    1. Silibello G, Vizziello P, Gallucci M, Selicorni A, Milani D, Ajmone PF, Rigamonti C, De Stefano S, Bedeschi MF, Lalatta F. Daily life changes and adaptations investigated in 154 families with a child suffering from a rare disability at a public Centre for rare diseases in northern Italy. Ital J Pediatr. 2016;42:76. doi: 10.1186/s13052-016-0285-0.
    1. Dellve L, Samuelsson L, Tallborn A, Fasth A, Hallberg LR. Stress and well-being among parents of children with rare diseases: a prospective intervention study. J Adv Nurs. 2006;53:392–402. doi: 10.1111/j.1365-2648.2006.03736.x.
    1. Benjamin K, Vernon MK, Patrick DL, Perfetto E, Nestler-Parr S, Burke L. Patient-Reported Outcome and Observer-reported outcome assessment in rare disease clinical trials - emerging good practices: an ISPOR COA emerging good practices report. Value Health. 2017;7:838–855. doi: 10.1016/j.jval.2017.05.015.
    1. Sabino G, Mills A, Jonker A, Lau LPL, Aartsma-Rus A, Arora J, Calvert M, Cano SJ, Denegri S, Hass S et al. Patient-centered outcome measures in the field of rare Diseases 2016. . Accessed 2 Sept 2017.
    1. Rotenstein LS, Huckman RS, Wagle NW. Making patients and doctors happier — the potential of patient-reported outcomes. N Engl J Med. 2017;377:1309–1312. doi: 10.1056/NEJMp1707537.
    1. FDA. Guidance for industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. US Department of Health and Human Services. 2009. . Accessed 7 Nov 2017.
    1. Howell D, Molloy S, Wilkinson K, Green E, Orchard K, Wang K, Liberty J. Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors. Ann Oncol. 2015;26:1846–1858. doi: 10.1093/annonc/mdv181.
    1. Streiner DL, Norman GR. Health measurement scales: a practical guide to their development and use, 4th edn. Oxford: Oxford University Press; 2008.
    1. Hendriksz CJ, Lavery C, Coker M, Ucar SK, Jain M, Bell L, Lampe C. Burden of disease in patients with Morquio a syndrome: results from an international patient-reported outcomes survey. Orphanet J Rare Dis. 2014;9:32. doi: 10.1186/1750-1172-9-32.
    1. Patrick DL, Burke LB, Powers JH, Scott JA, Rock EP, Dawisha S, O'Neill R, Kennedy DL. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health. 2007;10:S125–SS37. doi: 10.1111/j.1524-4733.2007.00275.x.
    1. Basch E, Geoghegan C, Coons S, et al. Patient-reported outcomes in cancer drug development and US regulatory review: perspectives from industry, the food and drug administration, and the patient. JAMA Oncol. 2015;1:375–379. doi: 10.1001/jamaoncol.2015.0530.
    1. EMA. Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man. The use of patient-reported outcome (PRO) measures in oncology studies: EMA; 2016. . Accessed 29 Jan 2018
    1. EMA. Reflection Paper on the use of patient reported outcome (PRO) measures in oncology studies: European Medicines Agency CfMPfHUC; 2014. . Accessed 8 Jan 2018
    1. Calvert M, Kyte D, Duffy H, Gheorghe A, Mercieca-Bebber R, Ives J, Draper H, Brundage M, Blazeby J, King M. Patient-reported outcome (PRO) assessment in clinical trials: a systematic review of guidance for trial protocol writers. PLoS One. 2014;9:e110216. doi: 10.1371/journal.pone.0110216.
    1. Deshpande PR, Rajan S, Sudeepthi BL, Abdul Nazir CP. Patient-reported outcomes: a new era in clinical research. Perspect Clin Res. 2011;2:137–144. doi: 10.4103/2229-3485.86879.
    1. Cohen JS, Biesecker BB. Quality of life in rare genetic conditions: a systematic review of the literature. Am J Med Genet A. 2010;152A:1136–1156. doi: 10.1002/ajmg.a.33380.
    1. Varni JW, Seid M, Rode CA. The PedsQL: measurement model for the pediatric quality of life inventory. Med Care. 1999;37:126–139. doi: 10.1097/00005650-199902000-00003.
    1. Ravens-Sieberer U, Herdman M, Devine J, Otto C, Bullinger M, Rose M, Klasen F. The European KIDSCREEN approach to measure quality of life and well-being in children: development, current application, and future advances. Qual Life Res. 2014;23:791–803. doi: 10.1007/s11136-013-0428-3.
    1. Bosch AM, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Koledova E, Benmedjahed K, Regnault A. Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries. Orphanet J Rare Dis. 2015;10:80. doi: 10.1186/s13023-015-0294-x.
    1. Regnault A, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Benmedjahed K, Bosch AM. Development and psychometric validation of measures to assess the impact of phenylketonuria and its dietary treatment on patients’ and parents’ quality of life: the phenylketonuria – quality of life (PKU-QOL) questionnaires. Orphanet J Rare Dis. 2015;10:59. doi: 10.1186/s13023-015-0261-6.
    1. Barry JA, Folkard A, Denniston AK, Moran E, Ayliffe W. Development and validation of quality-of-life questionnaires for birdshot Chorioretinopathy. Ophthalmology. 2014;121:1488–1489. doi: 10.1016/j.ophtha.2014.01.007.
    1. Zhang H, Wang L, Quan M, Huang J, Wu P, Lu Q, Fang Y. Health-related quality of life in children with chronic immune thrombocytopenia in China. Health Qual Life Outcomes. 2016;14:45. doi: 10.1186/s12955-016-0445-3.
    1. Ramaswami U, Stull DE, Parini R, Pintos-Morell G, Whybra C, Kalkum G, Rohrbach M, Raluy-Callado M, Beck M, Chen W-H, et al. Measuring patient experiences in Fabry disease: validation of the Fabry-specific pediatric health and pain questionnaire (FPHPQ) Health Qual Life Outcomes. 2012;10:116. doi: 10.1186/1477-7525-10-116.
    1. International Rare Diseases Consortium (IRDiRC). Patient-centred outcome measures initiatives in the field of rare diseases 2016. . Accessed 7 Nov 2017.
    1. Arends M, Hollak CEM, Biegstraaten M. Quality of life in patients with Fabry disease: a systematic review of the literature. Orphanet J Rare Dis. 2015;10:77. doi: 10.1186/s13023-015-0296-8.
    1. Hjollund INH, Larsen PL, Biering K, Johnsen PS, Riiskjær E, Schougaard ML. Use of patient-reported outcome (PRO) measures at group and patient levels: experiences from the generic integrated PRO system, WestChronic. Interact J Med Res. 2014;3:e5. doi: 10.2196/ijmr.2885.
    1. Jensen RE, Rothrock NE, DeWitt EM, Spiegel B, Tucker CA, Crane HM, Forrest CB, Patrick DL, Fredericksen R, Shulman LM, et al. The role of technical advances in the adoption and integration of patient-reported outcomes in clinical care. Med Care. 2015;53:153–159. doi: 10.1097/MLR.0000000000000289.
    1. Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, et al. Symptom monitoring with patient-reported outcomes during routine Cancer treatment: a randomized controlled trial. J Clin Oncol. 2016;34:557–565. doi: 10.1200/JCO.2015.63.0830.
    1. Snyder CF, Aaronson NK. Use of patient-reported outcomes in clinical practice. Lancet. 2009;374:369–370. doi: 10.1016/S0140-6736(09)61400-8.
    1. Luckett T, Butow PN, King MT. Improving patient outcomes through the routine use of patient-reported data in cancer clinics: future directions. Psychooncology. 2009;18:1129–1138. doi: 10.1002/pon.1545.
    1. Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101:1624–1632. doi: 10.1093/jnci/djp386.
    1. Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol. 2007;25:5121–5127. doi: 10.1200/JCO.2007.12.4784.
    1. Trujillano D, Oprea GE, Schmitz Y, Bertoli-Avella AM, Abou Jamra R, Rolfs A. A comprehensive global genotype–phenotype database for rare diseases. Mol Genet Genomic Med. 2017;5:66–75. doi: 10.1002/mgg3.262.
    1. Morel T, Cano SJ. Measuring what matters to rare disease patients – reflections on the work by the IRDiRC taskforce on patient-centered outcome measures. Orphanet J Rare Dis. 2017;12:171. doi: 10.1186/s13023-017-0718-x.
    1. patientslikeme. The value of Openess. . Accessed 13 Nov 2017.
    1. Newman SC, Bland RC, Orn H. A comparison of methods of scoring the general health questionnaire. Compr Psychiatry. 1988;29:402–8.
    1. NIHR. INVOLVE. . Accessed 5 Sept 2017.
    1. Basch E, Bennett AV. Patient-reported outcomes in clinical trials of rare diseases. J Gen Intern Med. 2014;29:801–803. doi: 10.1007/s11606-014-2892-z.
    1. Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, Litzow MR, Rivera CE, et al. The myelofibrosis symptom assessment form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009;33:1199–1203. doi: 10.1016/j.leukres.2009.01.035.
    1. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, et al. A double-blind placebo-controlled trial of Ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807. doi: 10.1056/NEJMoa1110557.
    1. Mesa RA, Kantarjian H, Tefferi A, Dueck A, Levy R, Vaddi K, Erickson-Viitanen S, Thomas DA, Cortes J, Borthakur G, et al. Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement. Cancer. 2011;117:4869–4877. doi: 10.1002/cncr.26129.
    1. Rodwell C, Ayme S. 2014 Report on the state of the art of rare disease activities in Europe. Scientific Secretariat of the European Union Committee of Experts on Rare Diseases (EUCERD) 2014. . Accessed 13 Nov 2017.
    1. Gliklich RE, Dreyer NA, Leavy MB. Registries for evaluating patient outcomes: a user’s guide . Accessed 14 Sept 2017.
    1. Renal Association. How to routinely collect data on patient reported outcomes and experience measures in renal registries in Europe: an expert consensus meeting. . Accessed 29 Sept 2017.
    1. Orphanet. Rare Disease Registries in Europe. Research IFNIfHaM. 2017. . Accessed 11 Nov 2017.
    1. Cystic Fibrosis Trust. UK CF Registry. . Accessed 15 Sept 2017.
    1. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Registry. . Accessed 15 Nov 2016.
    1. Fabry Registry. Fabry Registry: Creating knowledge on Fabry disease. . Accessed 11 Sept 2017.
    1. Pompe Community. Pompe Registry. . Accessed 19 Sept 2017.
    1. Gaucher Care. The Gaucher Registry. . Accessed 11 Sept 2017.
    1. Devlin NJ, Parkin D, Browne J. Patient-reported outcome measures in the NHS: new methods for analysing and reporting EQ-5D data. Health Econ. 2010;19:886–905. doi: 10.1002/hec.1608.
    1. Black N. Patient reported outcome measures could help transform healthcare. BMJ. 2013;346:f167. doi: 10.1136/bmj.f167.
    1. Calvert M, Thwaites R, Kyte D, Devlin N. Putting patient-reported outcomes on the ‘Big data road Map’. J R Soc Med. 2015;108:299–303. doi: 10.1177/0141076815579896.
    1. Kyte D, Cockwell P, Lencioni M, Skrybant M, von Hildebrand M, Price G, Squire K, Webb S, Brookes O, Fanning H, et al. Reflections on the national patient-reported outcome measures (PROMs) programme: where do we go from here? J R Soc Med. 2016;109(12):441–445. doi: 10.1177/0141076816677856.
    1. Frosch DL. Patient-reported outcomes as a measure of healthcare quality. J Gen Intern Med. 2015;30:1383–1384. doi: 10.1007/s11606-015-3476-2.
    1. ICHOM. /. Accessed.
    1. OMERACT. OMERACT resources. . Accessed Dec 2017.
    1. Prinsen CA, Vohra S, Rose MR, Boers M, Tugwell P, Clarke M, Williamson PR, Terwee CB. How to select outcome measurement instruments for outcomes included in a “Core outcome set” - a practical guideline. Trials. 2016;17:449. doi: 10.1186/s13063-016-1555-2.
    1. Terwee CB, Mokkink LB, Knol DL, Ostelo RWJG, Bouter LM, de Vet HCW. Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist. Qual Life Res. 2012;21:651–657. doi: 10.1007/s11136-011-9960-1.
    1. Mokkink LB, Terwee CB, Knol DL, Stratford PW, Alonso J, Patrick DL, Bouter LM, De Vet HCW. The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content. BMC Med Res Methodol. 2010;10:22. doi: 10.1186/1471-2288-10-22.
    1. Isa F, Turner G, Kyte D, Slade A, Pankhurst T, Kerecuk L, Keeley T, Ferguson J, Calvert M. Patient reported outcome measures used in patients with primary sclerosing cholangistis: systematic review. Copenhagen: ISOQOL; 2016.
    1. Younossi ZM, Afendy A, Stepanova M, Racila A, Nader F, Gomel R, Safer R, Lenderking WR, Skalicky A, Kleinman L, Myers RP, Subramanian GM, McHutchison JG, Levy C, Bowlus CL, Kowdley K, Muir AJ. Development and Validation of a Primary Sclerosing Cholangitis-Specific Patient-Reported Outcomes Instrument: The PSC PRO. Hepatology. 2018. Accepted Author Manuscript. 10.1002/hep.29664.
    1. Mapi Research Trust. ePROVIDE Online Support in Clinical Outcome Assessments. . Accessed 15 Sept 2017.
    1. Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, Ader D, Fries JF, Bruce B, Rose M. The patient-reported outcomes measurement information system (PROMIS): progress of an NIH roadmap cooperative group during its first two years. Med Care. 2007;45:S3–S11. doi: 10.1097/01.mlr.0000258615.42478.55.
    1. Bevans M, Ross A, Cella D. Patient-reported outcomes measurement information system (PROMIS(®)): efficient, standardized tools to measure self-reported health and quality of life. Nurs Outlook. 2014;62:339–345. doi: 10.1016/j.outlook.2014.05.009.
    1. van der Beek NAME, Hagemans MLC, van der Ploeg AT, van Doorn PA, Merkies ISJ. The Rasch-built Pompe-specific activity (R-PAct) scale. Neuromuscul Disord. 2013;23:256–264. doi: 10.1016/j.nmd.2012.10.024.
    1. Mattera MS, Kaplan FS, Pignolo RJ, Grogan D, Revicki DA. Patient-reported physical function outcome measure for adults with Fibrodysplasia Ossificans Progressiva: intelligent test design based on Promis item banks. Value Health. 2015;18:A165. doi: 10.1016/j.jval.2015.03.954.
    1. Hermans MCE, Hoeijmakers JGJ, Faber CG, Merkies ISJ. Reconstructing the Rasch-built myotonic dystrophy type 1 activity and participation scale. PLoS One. 2015;10:e0139944. doi: 10.1371/journal.pone.0139944.
    1. Wolfe E. Equating and item banking with the Rasch model. J Appl Meas. 2000;1:409.
    1. Pallant JF, Tennant A. An introduction to the Rasch measurement model: an example using the hospital anxiety and depression scale (HADS) Br J Clin Psychol. 2007;46:1–18. doi: 10.1348/014466506X96931.
    1. Du Y, Yates F. Rasch Measurement Transactions vol 9. 1995. When to adjust for differential item functioning; p. 414.
    1. Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, Erikson P. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation. Value Health. 2005;8:94–104. doi: 10.1111/j.1524-4733.2005.04054.x.
    1. Wild D, Eremenco S, Mear I, Martin M, Houchin C, Gawlicki M, Hareendran A, Wiklund I, Chong LY, von Maltzahn R, et al. Multinational trials—recommendations on the translations required, approaches to using the same language in different countries, and the approaches to support pooling the data: the ISPOR patient-reported outcomes translation and linguistic validation good research practices task force report. Value Health. 2009;12:430–440. doi: 10.1111/j.1524-4733.2008.00471.x.
    1. Regnault A, Herdman M. Using quantitative methods within the universalist model framework to explore the cross-cultural equivalence of patient-reported outcome instruments. Qual Life Res. 2015;24:115–124. doi: 10.1007/s11136-014-0722-8.
    1. Tennant A, Penta M, Tesio L, Grimby G, Thonnard JL, Slade A, Lawton G, Simone A, Carter J, Lundgren-Nilsson A, et al. Assessing and adjusting for cross-cultural validity of impairment and activity limitation scales through differential item functioning within the framework of the Rasch model - The PRO-ESOR project. Med Care. 2004;42:37–48. doi: 10.1097/01.mlr.0000103529.63132.77.
    1. Cano SJ, Mayhew A, Glanzman AM, Krosschell KJ, Swoboda KJ, Main M, Steffensen BF, BÉRard C, Girardot F, Payan CA, et al. Rasch analysis of clinical outcome measures in spinal muscular atrophy. Muscle Nerve. 2014;49:422–430. doi: 10.1002/mus.23937.
    1. Aiyegbusi OL, Kyte D, Cockwell P, Marshall T, Dutton M, Slade A, Marklew N, Price G, Verdi R, Waters J, et al. Using patient-reported outcome measures (PROMs) to promote quality of care and safety in the management of patients with advanced chronic kidney disease (PRO-trACK project): a mixed-methods project protocol. BMJ Open. 2017;7:e016687. doi: 10.1136/bmjopen-2017-016687.
    1. Zhu X, Cahan A. Wearable technologies and telehealth in Care Management for Chronic Illness. In: Weaver CA, Ball MJ, Kim GR, Kiel JM, editors. Healthcare Information management systems: cases, strategies, and solutions. Cham: springer international publishing; 2016. pp. 375–398.
    1. PCORI. Can Telehealth improve care? . Accessed 8 Jan 2018.
    1. PCORI. Patient-Centred Outcomes Research Institute. . Accessed 9 Jan 2018.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit